Novo Says May Take Years to Comply With FDA Request

Feb. 11 (Bloomberg) -- Novo Nordisk A/S Chief Executive Officer Lars Rebien Soerensen discusses the U.S. Food and Drug Administration's decision not to approve the insulin maker's Tresiba diabetes treatment, saying more data on heart safety is needed. He talks from Copenhagen with Francine Lacqua on Bloomberg Television's "On the Move." (Source: Bloomberg)
Is Tesla’s Downgrade an Opportunity for Investors
29:31 - IDDS Group co-founder and CEO Max Zanan and Jefferies Analyst Dan Dolev discuss the Tesla being downgraded with Emily Chang on “Bloomberg West.” (Source: Bloomberg)
  • Ukraine’s Jaresko: I'm Optimistic About Russia Bond Talks
  • Dell to Offer Data Storage Giant EMC $33 Per Share
  • Uber Closing In On 2014 Hack Suspect